Inquiry Basket
Loading ......
Filter By Product Search for
Nitrofurans
Nitrofurans Full Name
Nitrofurans
Nitrofurans Introduction
Nitrofuran drugs are a class of synthetic broad-spectrum antimicrobial agents characterized by a furan ring containing a nitro (-NO2) group. This family includes various compounds such as furazolidone, nitrofurazone, nitrofurantoin, and nifursol. However, the widespread use of these drugs has been accompanied by significant safety concerns. Substantial toxicological evidence indicates that many nitrofurans and their metabolites formed in living organisms pose potential risks of genotoxicity, mutagenicity, and carcinogenicity. These safety concerns have directly led to stringent global regulations on their use. Despite the safety controversies, nitrofuran drugs have played important roles in both human and veterinary medicine due to their broad-spectrum antibacterial activity. In veterinary practice, they were once widely used to prevent and treat bacterial and protozoan infections in poultry, pigs, and aquaculture species, and were even used in some cases as growth promoters. In contrast, within human medicine, certain members of the nitrofuran family, particularly nitrofurantoin, still maintain a clinical niche today. It is primarily used as a first- or second-line agent for treating or preventing acute uncomplicated urinary tract infections (UTIs). Its mechanism of action is unique: it achieves high concentrations in urine, effectively killing pathogens, while maintaining low levels in blood and tissues, thereby minimizing the risk of systemic side effects.
Figure 1. Chemical structures of nitrofurans and their respective metabolites. (Source: Chaisri N, et al. 2024)
The lethal action of nitrofuran drugs within bacteria involves a highly complex, metabolism-dependent, multi-target mechanism. First, these drugs are inert within the bacterial cell and must be activated by bacterial-specific nitroreductases (cytochrome P450 reductases). During this reduction process, the nitro group (-NO2) is converted into highly reactive intermediates such as nitro radicals, nitroso groups, and hydroxylamine. These reactive products can form covalent bonds with bacterial DNA, RNA, and proteins. This binding leads to DNA strand breaks, inhibition of RNA synthesis, and impairment of ribosomal protein synthesis, thereby disrupting fundamental bacterial metabolism and replication. Secondly, nitrofurans and their metabolites also interfere with the bacterial redox enzyme system. They can block metabolic pathways within the bacterial cell, such as inhibiting dehydrogenase systems or disrupting the Krebs cycle, leading to energy metabolism dysfunction. Because these drugs inhibit multiple key enzymes and metabolic pathways within the cell, they are often considered to possess a "multi-target" characteristic. This multi-target nature makes it difficult for bacteria to develop resistance through single gene mutations, which is one reason why resistance to nitrofuran drugs develops relatively slowly.
The use of nitrofuran drugs is associated with various adverse reactions and disease risks, the most prominent being pulmonary toxicity induced by nitrofurantoin and the carcinogenic risk associated with various nitrofuran compounds, particularly in the context of food residues. Firstly, nitrofurantoin-induced pulmonary toxicity is a clinically recognized, though uncommon, potentially serious adverse drug reaction. Its clinical manifestations are varied and can be divided into acute and chronic forms. Acute lung injury typically occurs within hours to days after drug administration, presenting with fever, chills, cough, dyspnea, and pulmonary infiltrates, which is considered a hypersensitivity reaction. Chronic pulmonary toxicity is more insidious, usually appearing after long-term use, and can lead to progressive dyspnea and interstitial pneumonia, potentially progressing to irreversible pulmonary fibrosis.
Alternate Names for Nitrofurans
Nitrofurans
Loading ......
